http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-94045125-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f3eeefcc365dc7cc077a4bccdbaa40d |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 1994-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa6350df679694c853fbf2fe3b46a19f |
| publicationDate | 1996-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-94045125-A |
| titleOfInvention | Method of treatment of uterus and ovary cancer |
| abstract | The invention relates to gynecological oncology and can be used to treat cancer of the uterus and ovaries of the III-1U stage. The objective of the invention is to reduce complications and increase the effectiveness of treatment. For this, the patient is preliminarily determined by sensitivity to the sodium salt of cyclic adenosine-3 ', 5'-monophosphate and, if there is one, the drug is administered at a concentration of 3.10 M intranasally, go sublingually 2 times a day every other day, starting with 6 drops on the first day and increasing the dose 2 drops per day in the following days, up to a total of 14 drops per day, after which the indicated dose is continued to be administered at the end of the course of treatment, which lasts 30 days. The invention allows to increase the survival time of severe patients, to reduce the number of complications and relapses. |
| priorityDate | 1994-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6076 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419553823 |
Total number of triples: 13.